These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 35632611)

  • 21. Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein.
    Reszka NJ; Dudek T; Knipe DM
    Vaccine; 2010 Mar; 28(15):2754-62. PubMed ID: 20117270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deletion of the S component inverted repeat sequence c' and the nonessential genes U(S)1 through U(S)5 from the herpes simplex virus type 1 genome substantially impairs productive viral infection in cell culture and pathogenesis in the rat central nervous system.
    Rasty S; Poliani PL; Fink DJ; Glorioso JC
    J Neurovirol; 1997 Aug; 3(4):247-64. PubMed ID: 9291233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dominant-negative herpesvirus protein inhibits intranuclear targeting of viral proteins: effects on DNA replication and late gene expression.
    McNamee EE; Taylor TJ; Knipe DM
    J Virol; 2000 Nov; 74(21):10122-31. PubMed ID: 11024141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing Viral Inhibition of Host Cellular Apoptosis Strengthens the Immunogenicity and Protective Efficacy of an Attenuated HSV-1 Strain.
    Xu X; He Y; Fan S; Feng M; Jiang G; Wang L; Zhang Y; Liao Y; Li Q
    Virol Sin; 2019 Dec; 34(6):673-687. PubMed ID: 31506828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection.
    Lu Z; Brans R; Akhrameyeva NV; Murakami N; Xu X; Yao F
    J Invest Dermatol; 2009 May; 129(5):1174-84. PubMed ID: 19005489
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Definition of herpes simplex virus type 1 helper activities for adeno-associated virus early replication events.
    Alazard-Dany N; Nicolas A; Ploquin A; Strasser R; Greco A; Epstein AL; Fraefel C; Salvetti A
    PLoS Pathog; 2009 Mar; 5(3):e1000340. PubMed ID: 19282980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Macrophages are important determinants of acute ocular HSV-1 infection in immunized mice.
    Mott K; Brick DJ; van Rooijen N; Ghiasi H
    Invest Ophthalmol Vis Sci; 2007 Dec; 48(12):5605-15. PubMed ID: 18055810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenovirus-mediated shRNA interference against HSV-1 replication in vitro.
    Song B; Liu X; Wang Q; Zhang R; Yang T; Han Z; Xu Y
    J Neurovirol; 2016 Dec; 22(6):799-807. PubMed ID: 27566181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A virus with a mutation in the ICP4-binding site in the L/ST promoter of herpes simplex virus type 1, but not a virus with a mutation in open reading frame P, exhibits cell-type-specific expression of gamma(1)34.5 transcripts and latency-associated transcripts.
    Lee LY; Schaffer PA
    J Virol; 1998 May; 72(5):4250-64. PubMed ID: 9557715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1.
    Morrison LA; Knipe DM
    Virology; 1996 Jun; 220(2):402-13. PubMed ID: 8661391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpes simplex virus type 1 prereplicative sites are a heterogeneous population: only a subset are likely to be precursors to replication compartments.
    Lukonis CJ; Burkham J; Weller SK
    J Virol; 1997 Jun; 71(6):4771-81. PubMed ID: 9151871
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of herpes simplex virus type 2 (HSV-2) viral replication by the dominant negative mutant polypeptide of HSV-1 origin binding protein.
    Yao F; Eriksson E
    Antiviral Res; 2002 Feb; 53(2):127-33. PubMed ID: 11750938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular infection of mice with an avirulent recombinant HSV-1 expressing IL-4 and an attenuated HSV-1 strain generates virulent recombinants in vivo.
    Mott KR; Wechsler SL; Ghiasi H
    Mol Vis; 2010 Oct; 16():2153-62. PubMed ID: 21139679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Mutation in the
    Dridi S; Richerioux N; Gonzalez Suarez CE; Vanharen M; Sanabria-Solano C; Pearson A
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A dominant mutant form of the herpes simplex virus ICP8 protein decreases viral late gene transcription.
    Chen YM; Knipe DM
    Virology; 1996 Jul; 221(2):281-90. PubMed ID: 8661438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficient establishment of reactivatable latency by an acyclovir-resistant herpes simplex virus 1 thymidine kinase substitution mutant with reduced neuronal replication.
    Wang S; Hou F; Yao YF; Pan D
    Virology; 2021 Apr; 556():140-148. PubMed ID: 33631413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of nuclear structures in cells infected with herpes simplex virus type 1 in the absence of viral DNA replication.
    Lukonis CJ; Weller SK
    J Virol; 1996 Mar; 70(3):1751-8. PubMed ID: 8627697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
    Royer DJ; Gurung HR; Jinkins JK; Geltz JJ; Wu JL; Halford WP; Carr DJJ
    J Virol; 2016 Jun; 90(11):5514-5529. PubMed ID: 27030264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.
    Da Costa X; Kramer MF; Zhu J; Brockman MA; Knipe DM
    J Virol; 2000 Sep; 74(17):7963-71. PubMed ID: 10933704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HSV-1 Hijacks the Host DNA Damage Response in Corneal Epithelial Cells through ICP4-Mediated Activation of ATM.
    Alekseev O; Donegan WE; Donovan KR; Limonnik V; Azizkhan-Clifford J
    Invest Ophthalmol Vis Sci; 2020 Jun; 61(6):39. PubMed ID: 32543665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.